(Q45960010)

18 December 2017

title

Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. (English)

1 reference

18 December 2017

author name string

R Beri

1

1 reference

18 December 2017

S Chunduri

2

1 reference

18 December 2017

K Sweiss

3

1 reference

18 December 2017

D J Peace

4

1 reference

18 December 2017

C Mactal-Haaf

5

1 reference

18 December 2017

L C Dobogai

6

1 reference

18 December 2017

S Shord

7

1 reference

18 December 2017

J G Quigley

8

1 reference

18 December 2017

Y H Chen

9

1 reference

18 December 2017

N Mahmud

10

1 reference

18 December 2017

D Rondelli

11

1 reference

18 December 2017

language of work or name

English

0 references

publication date

22 June 2009

1 reference

18 December 2017

Bone Marrow Transplantation

published in

1 reference

18 December 2017

volume

45

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

249-253

1 reference

18 December 2017

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

Plasma concentration monitoring of busulfan: does it improve clinical outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

Therapeutic drug monitoring of busulfan in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

7 January 2021

Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

7 January 2021

Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

7 January 2021

Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoi

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

7 January 2021

Lorazepam for seizure prophylaxis during high-dose busulfan administration

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

7 January 2021

Pharmacokinetic and metabolic studies of high-dose busulphan in adults

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.133

7 January 2021

Identifiers

DOI

10.1038/BMT.2009.133

1 reference

18 December 2017

Dimensions Publication ID

1015066376

0 references

1 reference

18 December 2017